Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors

Abstract Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well demonstrated in most GEP NETs, with the exception o...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Joo Young Kim, Jisup Kim, Yong-il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Subjects:	Somatostatin Receptor 2 Rectum Neuroendocrine tumor Prognosis
Online Access:	https://doi.org/10.1038/s41598-024-54599-4

Similar Items

Utility of Somatostatin Receptors in Gastrointestinal Tract and Pancreas Neuroendocrine Tumors
by: Kivilcim Eren ERDOGAN, et al.
Published: (2020-12-01)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
by: Maria Isabel del Olmo-Garcia, et al.
Published: (2021-12-01)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
by: Kristof Harda, et al.
Published: (2020-12-01)

Endoscopic treatment for rectal neuroendocrine tumor: which method is better?
by: Seung Min Hong, et al.
Published: (2022-07-01)

Molecular identification of somatostatin family in tilapia and the effect of food intake on pss2 and sstr3a
by: Ran Cai, et al.
Published: (2025-04-01)

Risk Factors for Lymph Node Metastasis and Oncologic Outcomes in Small Rectal Neuroendocrine Tumors with Lymphovascular Invasion
by: Seung-Joo Nam, et al.
Published: (2022-03-01)

Tumor grade 2 as the independent predictor for lymph node metastasis in 10–20 mm sized rectal neuroendocrine tumor
by: Byung-Soo Park, et al.
Published: (2021-06-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
by: Roberto eBaldelli
Published: (2014-02-01)

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
by: Sofia Koustoulidou, et al.
Published: (2022-09-01)

Natural Course of an Untreated Metastatic Perirectal Lymph Node After the Endoscopic Resection of a Rectal Neuroendocrine Tumor
by: Sang Hyung Kim, et al.
Published: (2015-04-01)

Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues
by: Manwar A. Mohammed AL-Naqqash
Published: (2016-01-01)

Primary pancreatic lymphoma camouflaged under the umbrella of spectrum of neuroendocrine tumors in somatostatin receptor imaging
by: Nikita Sampathirao, et al.
Published: (2020-07-01)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
by: Rihards Saksis, et al.
Published: (2023-02-01)

Efficacy of Precut Endoscopic Mucosal Resection for Treatment of Rectal Neuroendocrine Tumors
by: Hoonsub So, et al.
Published: (2017-11-01)

Rectal Neuroendocrine Tumor With Non‐Atypical Mucous Cell Glands: A Case Report
by: Akira Ishikawa, et al.
Published: (2025-07-01)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
by: Fernando Sebastian-Valles, et al.
Published: (2023-03-01)

The incidental diagnosis of a rectal neuroendocrine tumor after a segmental rectal resection for endometriosis
by: Antoine Naem, et al.
Published: (2023-12-01)

Somatostatin Receptor Imaging in the Diagnosis and Management of Parathyroid Neuroendocrine Neoplasia
by: Uliana Tsoy, et al.
Published: (2024-12-01)

Detection of Abdominal Lymph Node Metastasis from Pancreatic Neuroendocrine Tumor by Somatostatin Receptor Scintigraphy: Comparison with Somatostatin Receptor Type 2 Immunostaining
by: Kazuhiro Kitajima, et al.
Published: (2023-07-01)

Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours
by: Isuru Gamage, et al.
Published: (2025-07-01)

Stratification of rate of lymph node metastasis according to risk factors and oncologic outcomes in patients who underwent radical resection for rectal neuroendocrine tumors
by: Myung Jae Jin, et al.
Published: (2023-12-01)

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
by: Rosario Pivonello, et al.
Published: (2022-01-01)

Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review
by: Andreas Tartaglia, et al.
Published: (2022-07-01)

Somatostatin-SSTR3-GSK3 modulates human T-cell responses by inhibiting OXPHOS
by: Bo Zhang, et al.
Published: (2024-02-01)

Crosstalk of TGF-β and somatostatin signaling in adenocarcinoma and neuroendocrine tumors of the pancreas: a brief review
by: Hendrik Ungefroren, et al.
Published: (2025-03-01)

[89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors
by: Alexis M. Sanwick, et al.
Published: (2024-12-01)

Construction and evaluation of the prediction model for advanced disease in well-differentiated colorectal neuroendocrine neoplasms less than 2 cm in diameter
by: Hongda Yin, et al.
Published: (2025-01-01)

“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy
by: Sara Massironi, et al.
Published: (2025-02-01)

Laparoscopic versus open surgery for rectal neuroendocrine tumors: a multicenter real-world study
by: Xinyu Zeng, et al.
Published: (2024-08-01)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
by: Aadil Adnan, et al.
Published: (2023-06-01)

A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy
by: Pei Zhang, et al.
Published: (2025-10-01)

Comparison of 18F-FDG PET/CT and 18F-DOTATATE PET/CT in the diagnosis of multiple metastases in rectal neuroendocrine neoplasms
by: Zhihui Shen, BM, et al.
Published: (2024-09-01)

Prognostic marker of immunohistochemistry-based somatostatin receptors 2 and 5 H-scores in patients with pancreatic neuroendocrine neoplasms
by: Satomi Kono, et al.
Published: (2024-06-01)

Multiple distant metastases arising from a single, low-grade rectal neuroendocrine tumor: an autopsy case report
by: Keng Wee Goh, et al.
Published: (2023-03-01)

Somatostatin and Somatostatin-Containing Interneurons—From Plasticity to Pathology
by: Monika Liguz-Lecznar, et al.
Published: (2022-02-01)

Research Progress of Metal-Based Radiopharmaceuticals Targeting Somatostatin Receptor
by: QIN Xiang-yu, et al.
Published: (2023-04-01)

Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review
by: Anna La Salvia, et al.
Published: (2021-10-01)

Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report
by: Misato Ito, et al.
Published: (2020-06-01)

Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
by: Martin H. Cherk, et al.
Published: (2018-01-01)

Palliative primary tumor resection may not offer survival benefits for patients with unresectable metastatic colorectal neuroendocrine neoplasms, one multicenter retrospective cohort study
by: Guozhi Yu, et al.
Published: (2024-03-01)